GPOX Profile

OUR NEW PROFILE IS:        GPOX

  • GPOX is fully reporting OTCQB with just 29.3 million shares outstanding and sitting at 52 week lows at bottom of its range.

  • GPOX’s AntiGenTests.com currently has 3 different covid rapid test kits on sale: CareStart™ COVID-19 Antigen Test, Flowflex™ COVID-19 Antigen Test, and iHealth® COVID-19 Antigen Test

  • Due to the COVID test supply shortages, one of GPOX main value propositions has been getting tests delivered the next day! As a result GPOX revenues have ramped up in recent months

  • GPOX revenues have ramped up over the past few months with the Company reporting $598,719 in sales for the 6 months ended October 31, 2021 due to the rapid covid tests

  • GPOX is currently raising $5 million for expansion and acquisitons

See GPOX Investor Deck here

______________________________

Good Afternoon Traders,

Our New Profile is GPO Plus Inc (OTCMKTS: GPOX)

GPOX is fully reporting OTCQB with just 29.3 million shares outstanding and sitting at 52 week lows at bottom of its range.

GPOX has a compelling chart setup: fully reporting OTCQB GPOX has a history of big moves skyrocketing to highs over $4 per share in July 2020. The stock also spent most of 2021 over $2 per share. Currently at $0.51 GPOX is trading right at the bottom of its range and very near all-time lows.

GPO Plus Inc (OTCMKTS: GPOX)is a Group Purchasing Organization or “GPO” for the Healthcare industry. Headquartered in Las Vegas, Nevada, GPO Plus, Inc. (OTCQB:GPOX) is a publicly traded global holding company of industry-specific Group Purchasing Organizations (GPO). The main holdings are HealthGPO, a Group Purchasing Organization for the Healthcare industry, cbdGPO, a Group Purchasing Organization for the CBD and Hemp industry, and GPOPRO.

GPOX revenues have been growing fast over the past few months with the Company reporting $598,719 in sales for the 6 months ended October 31, 2021compared to just $30,627 for the same period last year. According to CEO Brett H. Pojunis the rapid growth in revenues in due in large part to POC COVID test sales at AntiGenTests.com.

GPOX is raising $5,000,000 from Accredited Investors under its Securities and Exchange Commission (SEC) Reg D 506c offering. “GPOX plans to grow and is looking to attract new shareholders that want to grow with us,” said Company CEO, Brett H. Pojunis. The details of the Company’s Private Placement Memorandum (PPM) and investor presentation can be found at https://invest.gpoplus.com

GPOX main holdings are HealthGPO, a Group Purchasing Organization for the Healthcare industry also operating AntiGenTests.com, cbdGPO, a Group Purchasing Organization for the CBD and Hemp industry, and GPOPRO.

GPOPRO

a wholly owned subsidiary company of GPOX Services include:

  • GPO PAY, low-cost reliable payment processing. GPOPlus+ works directly with institutions to provide low-cost and reliable payment processing services to our members.
  • GPO SAFE-SHIP, a licensed, insured, and bonded shipping solution for our members. The primary focus is b2b, however, GPO SHIP-SAFE can safely deliver products Direct To Consumers as well.
  • GPO INSURANCE, offering multiple types of insurance and coverage to our members.
  • GPO SUPPLIES. GPO Supplies include custom packaging, labels, lab equipment and materials, apparel, merchandise, general printing, and promotional items to all members.

cbdGPO

cbdGPO is a membership Group Purchasing Organization (“GPO” or “buying group”) created to help CBD companies including wholesalers, manufacturers, distributors, and labs realize savings and efficiencies by aggregating purchasing volume and using that leverage to negotiate discounts with manufacturers, distributors, and other vendors. Following the Federal legalization of Hemp-CBD products in the United States, there is an overwhelming demand for high quality Hemp-CBD products for both consumers as well as businesses looking to break into this lucrative industry. cbdGPO exists to make our members successful. Our purpose is to ensure our members deliver safe, cost-effective CBD products to consumers.

HealthGPO

As a solution-specific Group Purchasing Organization for the Healthcare industry, GPOX business is represented by an increasing number of offerings across the broad spectrum of medical supplies, to include emerging medical and preventative products. HealthGPO is committed to becoming an alternative option for all the needs of today’s healthcare industry. As demand has increased for medical products, HealthGPO is responding by offering quality proven products at discounts (usually substantial discounts) without having to place substantial orders. HealthGPO is a division of GPO Plus, Inc. (OTC:GPOX)

AntiGenTests.com is a project of HealthGPO, and its mission is to provide everyone with access to affordable, accurate Covid testing through our secure, sustainable supply chain, distribution network, and the power of Group Purchasing.

GPOX’s AntiGenTests.com currently has 3 different covid rapid test kits on sale:

CareStart™ COVID-19 Antigen Test

The CareStart™ COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigens from SARS-CoV-2.Under FDA’s EUA, the CareStart™ COVID-19 Antigen Home Test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with adult-collected nasal (nares) swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset.

This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 14 years or older, or adult-collected anterior nasal (nares) swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.

Flowflex™ COVID-19 Antigen Test

The FlowFlex™ COVID-19 Antigen Home Test is authorized for non-prescription home use with self-collected direct anterior nasal (nares) swab samples from individuals aged 14 years or older or adult collected direct anterior nasal swab samples from individuals aged two years or older. For use under an Emergency Use Authorization (EUA) only for the duration of the COVID-19 declaration justifying the emergency use of in vitro diagnostics (IVD), unless it is terminated or revoked by the FDA (after which the test may no longer be used)

RAPID DIAGNOSTIC TEST FOR THE DETECTION OF SARS-COV-2 ANTIGEN iHealth® Rapid Antigen Home Test – 2ct. Two (2) individual test per box. Rapid point-of-care (POC) test with results in minutes.

iHealth® COVID-19 Antigen Test

The iHealth® COVID-19 Antigen Rapid Test is a lateral flow assay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2. This test is authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with adult-collected nasal swab samples from individuals aged 2 years or older with symptoms of COVID-19 within the first 7 days of symptom onset. This test is also authorized for non-prescription home use with self-collected anterior nasal (nares) swab samples from individuals aged 15 years or older, or adult collected anterior nasal swab samples from individuals aged 2 years or older, with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests.

RAPID DIAGNOSTIC TEST FOR THE DETECTION OF SARS-COV-2 ANTIGEN iHealth® Rapid Antigen Home Test – 2ct. Two (2) individual test per box. Rapid point-of-care (POC) test with results in minutes

Regarding the Rapid Point-of-Care COVID-19 Antigen Tests GPOX President Ron McCormick stated: “Over the last year we (HealthGPO) have worked tirelessly to maintain a consistent supply of POC COVID tests while preserving the best and most competitive pricing available. One of the best things we’ve been able to do is to help POC facilities from getting massive fines. Due to the COVID test supply shortages, one of GPOX main value propositions has been getting tests delivered the next day! As long as the order is paid for by 6:00 PM Eastern, we can usually get the tests delivered the next business day. Now our members don’t have to worry about the supply chain issues.”

Rapid Point-of-Care COVID-19 Antigen Tests detect the presence or absence of SARS-CoV-2 viral protein which is the virus that causes COVID-19. Rapid Point-of-Care (POC) tests provide results within minutes (depending on the test) and are used to diagnose current or detect past SARS-CoV-2 infections in various settings, such as Physician offices, Urgent care facilities, Pharmacies, School health clinics, long term care facilities, and nursing homes, and temporary locations, such as drive-through sites managed by local organizations.

All COVID-19 tests distributed through AntigenTests.com are authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.AntigenTests.com is dedicated to Point-of-Care medical professionals.

During a recent interview, CEO Brett H. Pojunis discussed GPOX: (click here for interview)

  • the GPOX business model of creating industry-specific GPOscompared to business models of traditional Group Purchasing Organizations and/or Buying Groups
  • leadership’s focus on HealthGPO and further developing its business model the Company’s exiting stealth mode with a new sustainable and disruptive business model
  • how GPOX achieved a significant milestone generating over $1 Million in revenue
  • the expansion of its Leadership team to include a new Chief Financial Officer (CFO), Laurence Ruhe, and new President, Ron McCormick
  • the Company’s $5 Million Equity Crowdfunding Offering is open for the public and viewable at invest.gpoplus.com
  • why it’s a good time for investors to look at GPOPlus+, ticker: GPOX

__________

GPO PLUS INC. Brett H. Pojunis, CEO Laurence Ruhe, CFO Michael Fugler, Consultant Kevin G Malone, Consultant https://gpoplus.com/ https://healthgpo.com/ https://antigentests.com/

SECURITY DETAILS TICKER: OTCQB: GPOX OS: 29,332,509 MARKET CAP: $14,959,580

GPOX has a compelling chart setup: fully reporting OTCQB GPOX has a history of big moves skyrocketing to highs over $4 per share in July 2020. The stock also spent most of 2021 over $2 per share. Currently at $0.51 GPOX is trading right at the bottom of its range and very near all time lows.

GPOX RECENT NEWS

GPOPlus+ Announces the Launch of AntigenTests.com, a Project of HealthGPO

Press Release | 12/20/2021

LAS VEGAS, NV, Dec. 20, 2021 (GLOBE NEWSWIRE) — GPO Plus, Inc. (OTCQB: GPOX), a publicly traded company of diversified industry-specific Group Purchasing Organizations or “GPOs”, today announced the official launch of AntigenTests.com, a project of HealthGPO. HealthGPO is a Group Purchasing Organization for the Healthcare industry with operations and facilities located throughout the United States.

The purpose of AntigenTests.com is to provide HealthGPO Members and Point-of-Care providers with competitive pricing and a reliable supply chain for POC COVID-19 tests.

AntigenTests.com is a project created and managed by HealthGPO. HealthGPO started distributing FDA Emergency Use Authorization (EUA) Rapid Point-of-Care (POC) COVID-19 Antigen Tests and Rapid POC COVID-19 Antibody Tests in October 2020; immediately after the initial FDA EUA’s were granted.

AntigenTests.com solves two major problems typically associated with purchasing POC COVID-19 tests:

  1. Unreliable supply chains with global shortages, and
  2. Wildly inconsistent pricing with regular price increases.

HealthGPO addresses these problems with its dedicated team of procurement professionals to ensure its Members have extremely competitive pricing and a consistent and reliable supply chain for POC COVID-19 Antigen Tests and Antibody Tests.

  1. HealthGPO aggregates the purchasing power of its Members to negotiate discounts with suppliers that are then shared with its Members; saving its Members money!
  2. HealthGPO’s procurement team works with multiple distributors and vendors to secure the most popular POC COVID-19 tests; creating reliable supply chains!

Point-of-Care providers are encouraged to visit AntigenTests.com to review our pricing and sign up as a Member of HealthGPO. Since we are not charging membership fees at this time, to become a Member all you have to do is complete a purchase.

HealthGPO Members are always incentivized to spread the word because, in the spirit of Group Purchasing, our buying power increases with each new Member. The more buying power we have the better prices we can negotiate and the more money we save our Members!

GPOX President Ron McCormick said, “Over the last year we (HealthGPO) have worked tirelessly to maintain a consistent supply of POC COVID tests while preserving the best and most competitive pricing available.” McCormick Continued, “One of the best things we’ve been able to do is to help POC facilities from getting massive fines. Due to the COVID test supply shortages, one of our main value propositions has been getting tests delivered the next day! As long as the order is paid for by 6:00 PM Eastern, we can usually get the tests delivered the next business day. Now our Members don’t have to worry about the supply chain issues.”

“Shareholders who looked closely at our filings could identify that a large portion of our revenue last year (2021) was derived from POC COVID test sales,” said GPOX CEO Brett H. Pojunis. Pojunis continued, “The importance of this project (AntigenTests.com) cannot be overstated! With the emergence of new more contagious COVID variants such as Delta and Omicron, we believe the demand for COVID tests will continue to increase greatly leading to long term growth in this sector. This creates an opportunity for us to grow HealthGPO’s Membership because we are in a position to truly help POC healthcare and medical providers who are struggling to get the tests they need.”

Rapid Point-of-Care COVID-19 Antigen Tests detect the presence or absence of SARS-CoV-2 viral protein which is the virus that causes COVID-19. Rapid Point-of-Care (POC) tests provide results within minutes (depending on the test) and are used to diagnose current or detect past SARS-CoV-2 infections in various settings, such as Physician offices, Urgent care facilities, Pharmacies, School health clinics, long term care facilities, and nursing homes, and temporary locations, such as drive-through sites managed by local organizations.

All COVID-19 tests distributed through AntigenTests.com are authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. AntigenTests.com is dedicated to Point-of-Care medical professionals.

Equity Crowdfunding Page GPOX is raising $5,000,000 Please visit our crowdfunding page, https://invest.gpoplus.com

Sign up for your FREE account on the GPOX Investor Relations Portal:

Once you Activate your GPOX Investor Account you will have immediate access to real time information available on GPOX. Sign up for alerts (email and SMS) to be the first to know about news, SEC Filings, Investor Events, updated Investor Presentations, and more: www.GPOPlus.com/ir.

About AntigenTests.com

AntigenTests.com is a project created and managed by HealthGPO that has a dedicated team of procurement professionals to ensure our Members have a consistent supply chain for POC COVID-19 tests with competitive pricing.

Please visit: AntigenTests.com 

GPOX MANAGEMENT TEAM

Brett H. Pojunis, President, CEO, Treasurer, Secretary – Brett H. Pojunis is the Chairman and CEO of GPO Plus, Inc. Since 2014, Brett has served on the Board of Directors of a publicly traded company whose holdings include CBD and Cannabis projects. From Feb 2010 until Jan 2017, Brett was one of the leaders of the Libertarian Party serving two-terms on the Libertarian National Committee (LNC), two terms as the Chairman of the Libertarian Party of Nevada and was a part of the senior staff for the 2016 Johnson/Weld Presidential campaign. Brett has been involved in finance and the public markets since 1999 and has consulted and/or served on the Board of Directors of many start-up companies as well as publicly traded companies. From 2002 through October 2009, Brett has been involved in nightlife and entertainment ventures bridging technology and social media with events. He has hosted over 650 events in Las Vegas as well as other markets throughout the USA. Brett has military training ranging from Civil Affairs Specialist (38A) to Combat Engineer (12B). While in the US ARMY he was awarded the Outstanding American award twice. Brett is a fellow at The Leadership Institute which provides political activism training. Brett studied Environmental Liberal Arts at Green Mountain College and Entrepreneurship classes at the Simon School of Business at the University of Rochester. Brett attended elective International Business and Finance classes at Rochester Institute of Technology.

Laurence Ruhe, CFO – Laurence Ruhe is a seasoned professional with extensive experience in the capital markets driving strong financial and operational results for publicly traded and private companies. Mr. Ruhe has international business experience working with multi-national enterprises operating in multiple countries with multiple currencies. Mr. Ruhe brings over 34 years of financial and business experience to the Company, previously holding senior positions with Progressive Gaming, Konami Gaming, Wells Fargo, BMM International, Deutsche Bank, and other publicly traded companies. Mr. Ruhe joins the company as GPOX achieves its first financial milestone recently generating its first $1M in revenue (unaudited). As CFO, Mr. Ruhe will drive GPOXâs financial strategy and will lead the financial operations which include corporate finance, internal and external reporting, providing the Company with accounting oversight, and timely preparation of financial statements and related SEC filings. Additionally, Mr. Ruhe will help execute the Companyâs acquisitive growth strategy by providing oversight and managing the financial due diligence process of potential acquisition targets.

Kevin G Malone, Consultant – Kevin Malone, President, Secretary, Treasurer & Director, has been serving as a consultant to the Company since March 2014. Mr. Malone has served on the board of directors of US Highland Inc. (OTC Bulletin Board UHLN) from February 2013 – June 2017. Prior to joining US Highland Mr. Malone worked in the financial service industry since 1985. From March 2009 through October 2012, Mr. Malone served as head trader for R.F. Lafferty & Company, Inc. From January 2006 until March 2009, Mr. Malone worked in the same capacity at Westminster Securities Corporation. From December 2002 through January 2006, Mr. Malone worked for Aegis Capital Corporation.

Wayne Smeal has joined GPOX as its Chief Operating Officer (COO) – Wayne Smeal recently joined the team at GPOX last month becoming the Company’s Chief Operating Officer (COO) and a member of the board of directors. Mr. Smeal began his career working for Fortune 500 companies, including McKesson, Armor Food’s, ConAgra, and Kellogg’s. Mr. Smeal developed an international scalable franchise model in the indoor tanning industry with a company he founded called Executive Tan, with over 200 locations sold, employing over 600 employees and contractors, and annual Gross revenue of more than $20,000,000. He grew Executive Tans from a single location in 1991 to the largest indoor tanning company in the U.S. and the third-largest in the world by 2002. He was recognized by Ernst and Young Entrepreneur of the Year in 2005 and featured in Success Magazine and Entrepreneur Magazine where for 5 consecutive years Executive Tans appeared on the Top 500 Franchise Global Rankings. Prior to joining GPOX, Mr. Smeal was a pioneer in the CBD industry. He was a partner in and revamped the sales and operations of a company reorganizing numerous departments including restructuring the sales and marketing departments and successfully launched over 50 new CBD products throughout all 50 states and 7 countries.

GPOX NEWS

Sincerely,

DISCLAIMER

*****WE HAVE BEEN COMPENSATED FOR THIS EMAIL.
THIS WEBSITE/NEWSLETTER IS A WHOLLY OWNED SUBSIDIARY OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22, LLC
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.  WE HAVE BEEN COMPENSATED A FEE OF TWENTY FIVE THOUSAND USD BY A THIRD PARTY, BULLZEYE MEDIA, LLC FOR A ONE DAY GPOX AWARENESS CAMPAIGN.   ON OCT, 7, 2021. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: O22 LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.  RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD O22, LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND O22, LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD O22, LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.O22, LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. O22, LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, ANDO22, LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.IN PREPARING THIS PUBLICATION,O22, LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22, LLC HAS NOT BEEN COMPENSATED FOR THIS EMAIL. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, O22, LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. O22, LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS O22, LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. 022, LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA. 
GET NOTIFIED
I agree to have my personal information transfered to iContact ( more information )
Sign up for our next MicroCap Runner ahead of the crowd!
We hate spam. No Hidden Fees. Unsubscribe Anytime.
content-main